Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (STABL) - Net Assets
Latest net assets as of September 2025: Skr8.46 Million SEK
Based on the latest financial reports, Stayble Therapeutics AB (STABL) has net assets worth Skr8.46 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr9.90 Million) and total liabilities (Skr1.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr8.46 Million |
| % of Total Assets | 85.43% |
| Annual Growth Rate | -5.77% |
| 5-Year Change | -55.8% |
| 10-Year Change | N/A |
| Growth Volatility | 77.35 |
Stayble Therapeutics AB - Net Assets Trend (2016–2024)
This chart illustrates how Stayble Therapeutics AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Stayble Therapeutics AB (2016–2024)
The table below shows the annual net assets of Stayble Therapeutics AB from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr6.87 Million | -58.37% |
| 2023-12-31 | Skr16.51 Million | +8.02% |
| 2022-12-31 | Skr15.28 Million | -61.61% |
| 2021-12-31 | Skr39.81 Million | +156.02% |
| 2020-12-31 | Skr15.55 Million | +5362.88% |
| 2019-12-31 | Skr-295.44K | -104.15% |
| 2018-12-31 | Skr7.11 Million | -13.75% |
| 2017-12-31 | Skr8.25 Million | -25.44% |
| 2016-12-31 | Skr11.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Stayble Therapeutics AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1121420000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr5.68 Million | 82.70% |
| Other Comprehensive Income | Skr1.92 Million | 27.96% |
| Other Components | Skr11.69 Million | 170.01% |
| Total Equity | Skr6.87 Million | 100.00% |
Stayble Therapeutics AB Competitors by Market Cap
The table below lists competitors of Stayble Therapeutics AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UNITED PARCEL SVC-B - Dusseldorf Stock Exchang
DU:UPAB
|
$857.18K |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
$857.31K |
|
Silicon Gaming Inc
PINK:SGIC
|
$858.28K |
|
Exro Technologies Inc
OTCQB:EXROF
|
$859.20K |
|
Av Gad Holdings Ltd
TA:AVGD
|
$855.64K |
|
HUA YIN INTL HLDGS LTD
F:CL7
|
$855.03K |
|
ZWACK UNICUM
MU:ZWC1
|
$854.97K |
|
BBS-Bioactive Bone Substitutes Oyj
HE:BONEH
|
$854.55K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stayble Therapeutics AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 16,507,933 to 6,873,000, a change of -9,634,933 (-58.4%).
- Net loss of 12,418,000 reduced equity.
- New share issuances of 3,000,000 increased equity.
- Other comprehensive income decreased equity by 820.
- Other factors decreased equity by 216,113.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-12.42 Million | -180.68% |
| Share Issuances | Skr3.00 Million | +43.65% |
| Other Comprehensive Income | Skr-820.00 | -0.01% |
| Other Changes | Skr-216.11K | -3.14% |
| Total Change | Skr- | -58.37% |
Book Value vs Market Value Analysis
This analysis compares Stayble Therapeutics AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.94x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.14x to 0.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr1.24 | Skr0.17 | x |
| 2017-12-31 | Skr0.92 | Skr0.17 | x |
| 2018-12-31 | Skr0.80 | Skr0.17 | x |
| 2019-12-31 | Skr-0.06 | Skr0.17 | x |
| 2020-12-31 | Skr1.74 | Skr0.17 | x |
| 2021-12-31 | Skr2.80 | Skr0.17 | x |
| 2022-12-31 | Skr1.07 | Skr0.17 | x |
| 2023-12-31 | Skr0.64 | Skr0.17 | x |
| 2024-12-31 | Skr0.18 | Skr0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stayble Therapeutics AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -180.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.35x
- Recent ROE (-180.68%) is below the historical average (-82.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -10.88% | -3390.99% | 0.00x | 1.10x | Skr-2.31 Million |
| 2017 | -34.12% | 0.00% | 0.00x | 1.15x | Skr-3.64 Million |
| 2018 | -86.25% | -15293.69% | 0.00x | 1.27x | Skr-6.85 Million |
| 2019 | 0.00% | -1377242.37% | 0.00x | 0.00x | Skr-7.38 Million |
| 2020 | -99.61% | 0.00% | 0.00x | 1.16x | Skr-17.04 Million |
| 2021 | -30.25% | 0.00% | 0.00x | 1.10x | Skr-16.02 Million |
| 2022 | -160.49% | 0.00% | 0.00x | 1.25x | Skr-26.05 Million |
| 2023 | -143.79% | 0.00% | 0.00x | 1.31x | Skr-25.39 Million |
| 2024 | -180.68% | 0.00% | 0.00x | 1.35x | Skr-13.11 Million |
Industry Comparison
This section compares Stayble Therapeutics AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stayble Therapeutics AB (STABL) | Skr8.46 Million | -10.88% | 0.17x | $856.35K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |